MannKind Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to
Type 1
MannKind Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for …
Today’s Diabetes News, your ultimate destination for up-to-date and insightful information on diabetes, health tips, and living a fulfilling life with diabetes. Our mission is to empower and support individuals with diabetes, their loved ones, and the wider community by providing reliable, relevant, and engaging content that fosters a healthier and happier life.
Copyright MatchingDonors.com©️ 2025 All rights reserved.
tag -->